Hims' moat is data, not drug dispensing
Paul Serra argued the market is overly focused on Hims & Hers Health's ability to market and dispense drugs, but the real long-term value and defensible moat lies in its ability to collect and utilize patient data to improve retention and lifetime value.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.